📊 Full opportunity report: Find Current GLP-1 Stock And Dose Options By Pharmacy on IdeaNavigator AI — validation score, market gap, and execution plan.
Get the latest gadgets delivered free — and shop member deals
- Fast, free delivery on millions of items
- Access to Prime Big Deal Days deals on October 6–7
- Prime Video, Amazon Music and more included
TL;DR
IdeaNavigator AI has proposed a pharmacy index that would help patients compare stock and cash prices for four brand-name GLP-1 drugs by dose and ZIP code. The concept is a proposed product, not a launched service; its price and availability data would need ongoing verification.
IdeaNavigator AI has proposed a GLP-1 pharmacy index that would let patients search cash prices and reported stock for specific doses by ZIP code, while selling normalized availability and pricing data to businesses. The concept addresses fragmented information after federal shortage listings ended, but the index has not been described as launched and its data would require verification.
The proposed free consumer tool would cover Ozempic, Wegovy, Zepbound and Mounjaro. Users would select a drug, dose and ZIP code to look for reported availability and compare cash prices across manufacturer-direct programs and retailers, including LillyDirect, NovoCare, Costco and Walmart. The plan also calls for a price comparison layer similar to coupon services and alerts when a requested dose becomes available.
IdeaNavigator AI proposes starting with crowdsourced stock reports and normalized public pricing information. The dataset could later be licensed through an API or dashboard to telehealth prescribers, employer benefits teams, benefits brokers and pharmacy benefit managers. The proposal identifies referral fees to legitimate pharmacy or manufacturer-direct channels as another possible revenue stream; it does not describe commissions tied to prescribing a drug.
The suggested validation would run for 60 days in one metro area. The proposal sets two targets: at least 200 consumer stock reports and paid pilots or letters of intent from at least two business prospects. These are proposed success measures, not achieved results. No metro, participating pharmacy network, customer commitments or operating product is identified.
Why Dose-Level Price Data Matters
Patients can face different cash prices depending on the product, dose and purchase channel, while a pharmacy may have one strength in stock and another unavailable. A searchable index could make these differences easier to compare and help patients locate a legitimate source without checking each seller separately. The proposal cites a broad range of roughly $199 to more than $1,000 per month, but does not specify the products, doses, dates or terms behind each price. That range should be treated as an illustration in the proposal, not a live price comparison.
For employers and other benefit buyers, a normalized feed could help track costs and availability across channels. The proposal says GLP-1 medicines account for roughly 20% of pharmacy spending for employers, but gives no survey, time period or calculation method for that figure. If validated, reliable dose-level data could support purchasing and coverage decisions; inaccurate or stale listings could instead send patients to locations that cannot fill a prescription or quote a price that no longer applies.
From Shortage Lists to Fragmented Channels
The proposal describes a shift from national shortage concerns to localized differences in stock and price. It says the FDA determined shortages of tirzepatide in December 2024 and semaglutide in February 2025 had been resolved. Those determinations concern the listed drugs’ shortage status; they do not establish that every pharmacy has every dose available at a given time.
In the proposal’s account, manufacturer-direct cash-pay options and retailer programs have multiplied the places patients may need to check. It also points to changes affecting compounded versions and the launch of the TrumpRx portal in February 2026 as factors in a more fragmented market. The proposed index would aggregate information across these channels rather than serve as a pharmacy or prescriber. It would not establish clinical suitability, insurance coverage or eligibility for a manufacturer program.
Data Accuracy and Buyer Demand
No operating index or independently verified feed is described. The proposal does not say how often prices and stock reports would be checked, how crowdsourced reports would be confirmed, or how quickly outdated listings would be removed. It also does not identify participating pharmacies or explain how it would distinguish a temporary stock report from confirmed inventory.
Other open questions include the business buyers’ willingness to pay, the completeness of public price information and the final scope of covered doses and channels. Cash prices may depend on program conditions or patient eligibility, details not set out in the proposal. The 200-report and two-prospect targets remain goals; no results are reported.
The Proposed 60-Day Market Test
The next step outlined by IdeaNavigator AI is a single-metro test of a consumer search page and a business-facing pitch for the data feed. The plan would assess whether patients submit enough reports to make local listings useful and whether telehealth or employer-benefits buyers agree to paid pilots or letters of intent.
Any resulting index would need to show when each price and availability report was collected, explain how entries are checked, and make clear that listings can change. The proposal gives no start date or public release schedule, so whether the test will proceed and what it finds remain unknown.
Key Questions
Is the GLP-1 pharmacy index available now?
No launch is reported. IdeaNavigator AI has outlined a proposal and a 60-day validation plan, but does not identify a live tool or release date.
Which medicines would the proposed index cover?
The proposed first version names Ozempic, Wegovy, Zepbound and Mounjaro, searchable by drug, dose and ZIP code.
Would the index guarantee that a dose is in stock?
No such guarantee is described. The concept relies partly on crowdsourced reports and public price information, and the proposal does not specify a verification system or update schedule.
How would the proposed service make money?
The plan calls for a free consumer finder and paid availability and price data for telehealth providers, employers, benefits brokers and pharmacy benefit managers. It also mentions possible referral fees to legitimate pharmacy or manufacturer-direct channels.
Source: IdeaNavigator AI
Fall Picks
fall essentials
As an affiliate, we earn on qualifying purchases.
